We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Merck, Intel, MercadoLibre, The Travelers Companies and Halliburton
Read MoreHide Full Article
For Immediate Release
Chicago, IL – March 22, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Merck & Co., Inc. (MRK - Free Report) , Intel Corp. (INTC - Free Report) , MercadoLibre, Inc. (MELI - Free Report) , The Travelers Companies, Inc. (TRV - Free Report) and Halliburton Co. (HAL - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Research Reports for Merck, Intel and Mercado Libre
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc., Intel Corp. and MercadoLibre, Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Merck have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+33.5% vs. +2.2%). The company's products like Keytruda and Gardasil have been driving sales. With continued label expansion into new indications & early-stage settings, Keytruda is expected to remain a key top-line driver.
Animal health and vaccine products are core growth drivers. Merck boasts a strong cancer pipeline, including Keytruda, which should drive long-term growth.
However, generic competition for several drugs and rising competitive pressure, mainly on the diabetes franchise, will continue to be overhangs on the top line. There are concerns about Merck's ability to grow its non-oncology business ahead of Keytruda's loss of exclusivity later in the decade.
Intel's shares have underperformed the Zacks Semiconductor - General industry over the past year (-39.8% vs. -9.7%). The company is facing a challenging macroeconomic environment, uncertain business conditions and softening demand trends are likely to remain an overhang on Intel's performance. In addition, production delays remain a concern.
Imposition of fresh lockdown restrictions in some markets, forex woes and high debt burden are other headwinds. Intensifying competition, inflated raw material costs and signs of market saturation are worrisome.
However, Intel is gaining rapid strides in the data center business with integrated solutions that are highly competitive in prices. The company is also focusing on developing a complete product range targeting different segments of the market. Healthy traction from Mobileye's technologies related to cameras, in-car networking, sensor-chips, roadway mapping, cloud software, machine learning and data management are tailwinds.
Shares of MercadoLibre have outperformed the Zacks Internet - Commerce industry over the past six months (+39.2% vs. -9.7%). The company is benefiting from strength in the commerce and fintech businesses. Robust product offerings and credit portfolio expansion are respectively driving the company's commerce and fintech revenues.
Further, robust mobile-point-of-sale business and growing adoption of MercadoPago are driving the total payment volume growth of the company. Our estimate suggests that the total payment volume is likely to witness a 30% rise in the current year from last year's figure.
Also, rapid adoption of Mobile Wallet remains a positive. Further, robust shipment growth via MercadoEnvios is another positive. However, mounting expenses related to warehousing, free shipping subsidies and mPOS discounts remain overhangs.
Other noteworthy reports we are featuring today include The Travelers Companies, Inc. and Halliburton Co..
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
The Zacks Analyst Blog Highlights Merck, Intel, MercadoLibre, The Travelers Companies and Halliburton
For Immediate Release
Chicago, IL – March 22, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Merck & Co., Inc. (MRK - Free Report) , Intel Corp. (INTC - Free Report) , MercadoLibre, Inc. (MELI - Free Report) , The Travelers Companies, Inc. (TRV - Free Report) and Halliburton Co. (HAL - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Research Reports for Merck, Intel and Mercado Libre
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc., Intel Corp. and MercadoLibre, Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of Merck have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+33.5% vs. +2.2%). The company's products like Keytruda and Gardasil have been driving sales. With continued label expansion into new indications & early-stage settings, Keytruda is expected to remain a key top-line driver.
Animal health and vaccine products are core growth drivers. Merck boasts a strong cancer pipeline, including Keytruda, which should drive long-term growth.
However, generic competition for several drugs and rising competitive pressure, mainly on the diabetes franchise, will continue to be overhangs on the top line. There are concerns about Merck's ability to grow its non-oncology business ahead of Keytruda's loss of exclusivity later in the decade.
(You can read the full research report on Merck here >>>)
Intel's shares have underperformed the Zacks Semiconductor - General industry over the past year (-39.8% vs. -9.7%). The company is facing a challenging macroeconomic environment, uncertain business conditions and softening demand trends are likely to remain an overhang on Intel's performance. In addition, production delays remain a concern.
Imposition of fresh lockdown restrictions in some markets, forex woes and high debt burden are other headwinds. Intensifying competition, inflated raw material costs and signs of market saturation are worrisome.
However, Intel is gaining rapid strides in the data center business with integrated solutions that are highly competitive in prices. The company is also focusing on developing a complete product range targeting different segments of the market. Healthy traction from Mobileye's technologies related to cameras, in-car networking, sensor-chips, roadway mapping, cloud software, machine learning and data management are tailwinds.
(You can read the full research report on Intel here >>>)
Shares of MercadoLibre have outperformed the Zacks Internet - Commerce industry over the past six months (+39.2% vs. -9.7%). The company is benefiting from strength in the commerce and fintech businesses. Robust product offerings and credit portfolio expansion are respectively driving the company's commerce and fintech revenues.
Further, robust mobile-point-of-sale business and growing adoption of MercadoPago are driving the total payment volume growth of the company. Our estimate suggests that the total payment volume is likely to witness a 30% rise in the current year from last year's figure.
Also, rapid adoption of Mobile Wallet remains a positive. Further, robust shipment growth via MercadoEnvios is another positive. However, mounting expenses related to warehousing, free shipping subsidies and mPOS discounts remain overhangs.
(You can read the full research report on MercadoLibre here >>>)
Other noteworthy reports we are featuring today include The Travelers Companies, Inc. and Halliburton Co..
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.